The narrative presents a compelling vision of cell and gene therapies transitioning from niche, high-cost treatments to scalable, life-changing solutions for millions. The strongest version of this story highlights genuine scientific progress—advances in vector engineering, decentralized manufacturing, and regulatory initiatives like CGTxchange—all aimed at overcoming longstanding barriers to access. The shift toward in vivo therapies and the flurry of billion-dollar deals suggest a maturing ind...